Literature DB >> 26819138

Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review.

A Kristensen1, O M Vagnildhaug2, B H Grønberg2, S Kaasa2, B Laird3, T S Solheim2.   

Abstract

Chemotherapy is increasingly being used in advanced pancreatic cancer, but side-effects are common. The aim of this systematic review was to assess whether chemotherapy improves health-related quality of life (HRQoL), pain or cachexia. Thirty studies were reviewed. Four of 23 studies evaluating HRQoL, 7 of 24 studies evaluating pain and 0 of 8 studies evaluating cachexia found differences between treatment arms. Change in HRQoL from baseline was evaluated in 14 studies: five studies reported an improvement in at least one treatment arm; three a worsening and the remaining stable scores. Change in pain intensity from baseline was evaluated in eight studies, and improvement was observed in seven. Of the four studies reporting improved survival, three reported improved HRQoL or pain. In conclusion, chemotherapy can stabilize HRQoL and improve pain control. Effects on cachexia are hard to elucidate. Improved survival does not come at the expense of HRQoL or pain control.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cachexia; Chemotherapy; Pain; Pancreatic Cancer; Quality of Life; Systematic review

Mesh:

Substances:

Year:  2016        PMID: 26819138     DOI: 10.1016/j.critrevonc.2016.01.006

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  19 in total

1.  Physical Inactivity and Pancreatic Cancer Mortality.

Authors:  Megha Pratapwar; Ashley E Stenzel; Janine M Joseph; Christos Fountzilas; John Lewis Etter; Jennifer M Mongiovi; Rikki Cannioto; Kirsten B Moysich
Journal:  J Gastrointest Cancer       Date:  2020-09

Review 2.  Pain in Patients with Pancreatic Cancer: Prevalence, Mechanisms, Management and Future Developments.

Authors:  Andreas I Koulouris; Paul Banim; Andrew R Hart
Journal:  Dig Dis Sci       Date:  2017-02-22       Impact factor: 3.199

3.  Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer.

Authors:  Vincent Picozzi; Siva Narayanan; X Henry Hu; Jeffrey Vacirca
Journal:  J Gastrointest Cancer       Date:  2017-03

4.  Utilization and trends in palliative therapy for stage IV pancreatic adenocarcinoma patients: a U.S. population-based study.

Authors:  Audrey S Kulaylat; Katelin A Mirkin; Christopher S Hollenbeak; Joyce Wong
Journal:  J Gastrointest Oncol       Date:  2017-08

5.  Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: a nation-wide study.

Authors:  Ibrahim Azar; Gurjiwan Virk; Saghi Esfandiarifard; Ali Wazir; Syed Mehdi
Journal:  J Gastrointest Oncol       Date:  2019-08

6.  The association between different opioid doses and the survival of advanced cancer patients receiving palliative care.

Authors:  Anon Sathornviriyapong; Kittiphon Nagaviroj; Thunyarat Anothaisintawee
Journal:  BMC Palliat Care       Date:  2016-11-21       Impact factor: 3.234

7.  Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer.

Authors:  E Gabriela Chiorean; Daniel Von Hoff; Yin Wan; Sandra Margunato-Debay; Marc Botteman; David Goldstein
Journal:  Cancer Manag Res       Date:  2018-05-31       Impact factor: 3.989

8.  Meta‑analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment‑associated toxicities.

Authors:  Jie Chen; Linli Chen; Jianping Yu; Yanmei Xu; Xiaohui Wang; Ziqian Zeng; Ning Liu; Fan Xu; Shu Yang
Journal:  Mol Med Rep       Date:  2018-11-09       Impact factor: 2.952

9.  Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.

Authors:  Berta Laquente; Teresa Macarulla; Cristina Bugés; Marta Martín; Carlos García; Carles Pericay; Sandra Merino; Laura Visa; Teresa Martín; Manuela Pedraza; Beatriz Carnero; Raquel Guardeño; Helena Verdaguer; Alejandro Mut; David Vilanova; Adelaida García
Journal:  BMC Palliat Care       Date:  2020-07-10       Impact factor: 3.234

10.  Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer.

Authors:  Wanyuan Chen; Weimin Fan; Guoqing Ru; Fang Huang; Xiaming Lu; Xin Zhang; Xiaozhou Mou; Shibing Wang
Journal:  Oncol Rep       Date:  2018-10-24       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.